There are contraindications! Be sure to consult your doctor before taking any medication!
Olmesar is an antihypertensive agent, angiotensin II receptor blocker. This medication has a high selectivity to angiotensin II receptor type 1 (AT1) which are implemented with the participation of the main effects of angiotensin II. By blocking these receptors Olmesar prevents and eliminates the vasoconstrictor action of angiotensin II, causes a secondary increase in plasma renin activity due to elimination of negative feedback for renin release and a direct reduction in aldosterone secretion.
When hypertension Olmesar causes dose-dependent, prolonged reduction of blood pressure.
There are no details about the development of arterial hypotension after the first dose of Olmesar, tachyphylaxis during prolonged treatment and withdrawal.
When taking first time Olmesar provides an effective and mild reduction of blood pressure within 24 hours. Maximum antihypertensive effect is achieved after 8 weeks of the therapy, although a significant effect of blood pressure lowering marked only in 2 weeks of the treatment.
Olmesar is a pro-drug. It quickly turns into a pharmacologically active metabolite of olmesartan under the influence of esterases in the intestinal mucosa and blood of portal vein during absorption from the gastrointestinal tract. In blood plasma or secretions nondecomposed Olmesar or unmodified side chain medoxomil group was not been determined. Cmax of olmesartan in plasma levels reached an average of approximately 2 hours after ingestion and increases almost linearly with increasing dose to 80 mg. Simultaneous ingestion does not affect the bioavailability of olmesartan. Olmesartan binding to plasma proteins is 99.7% but the potential for clinically significant shift values of binding to proteins in the interaction of olmesartan with other drugs that have a high degree of protein binding is low (this is confirmed by the fact that there is no clinically significant interaction between warfarin and olmesartan). Olmesartan is excreted in the urine (approximately 40%) and bile (approximately 60%), T1/2 is 10-15 hours. Cumulation of olmesartan is not marked.
Why is Olmesar prescribed?
Essential arterial hypertension.
Dosage and administration
Olmesar is administered orally on a daily basis. The initial dose is 10 mg / day. When inefficiency the dose increases up to the optimum 20 mg / day. If necessary the dose may be increased to the maximum 40 mg / day.
For elderly patients dosage adjustment is not required. If necessary increasing the daily dose to a maximum of 40 mg / day improvement should be under careful control of blood pressure. For patients with impaired mild or moderate renal function (creatinine clearance 20-60 ml / min) the maximum daily dose is 20 mg.
Musculoskeletal system: arthritis, back pain, bone pain, muscle cramps, myalgia, increased activity of CK.Urinary system: hematuria, urinary tract infection.
Metabolism: hypertriglyceridemia, hyperuricemia, hyperkalemia, increased serum creatinine and urea in serum, peripheral edema.
Other: chest pain, flu-like symptoms.
Obstruction of the biliary tract, pregnancy, lactation, childhood and adolescence under the age of 18 years.
Using during pregnancy and breastfeeding
Olmesar is contraindicated for use during pregnancy and lactation (breastfeeding).
Due to the lack of sufficient clinical experience does not recommended the use of Olmesar in patients with severe renal insufficiency (creatinine clearance < 20 mL / min), patients with impaired liver function.
Olmesar used with caution in patients with stenosis of the aortic or mitral valves or obstructive hypertrophic cardiomyopathy.
In the case of previous intensive therapy with diuretics, human salt-free diet, diarrhea and / or vomiting after the first dose may been developed hypotension as a result of reducing the BCC. Thats why it is necessary to eliminate the possibility of hypovolemia before starting treatment with olmesartan medoxomil.
Olmesar should be used with caution for patients with heart failure, kidney disease, renal artery stenosis in both or only one kidney because of the risk of acute hypotension, azotemia, oliguria, acute renal failure.
When treating patients with impaired renal function it is recommended periodic monitoring of potassium and creatinine in serum.
It is not recommended of Olmesar using in patients with primary hyperaldosteronism.
It should be borne in mind that excessive lowering of blood pressure in patients with coronary artery disease or atherosclerosis of cerebral vessels may lead to the development of myocardial infarction or ischemic stroke.
While taking of Olmesar occasionally there may be dizziness or fatigue which should be considered in the application of patients, control of vehicles and / or engaged in other potentially hazardous activities.
Olmesar drug interactions
Simultaneous administration of Olmesar with:
other antihypertensive drugs may increase the hypotensive effect;
NSAIDs may reduce hypotensive effects and increased risk of acute renal failure;
after therapy with antacids (magnesium aluminum hydroxide) there was detected of decreasing bioavailability of olmesartan medoxomil;
lithium medications increases the toxicity of the latter (the combination is not recommended).The risk of developing hyperkalemia is increased while the taking of Olmesar with potassium-sparing diuretics, medications containing potassium or with other drugs that can cause increased potassium levels in blood serum, for example, with heparin (a combination not recommended).
Olmesar in case of emergency / overdose
Symptoms: pronounced reduction in blood pressure, tachycardia.
Treatment: when pronounced reduction of blood pressure is recommended to lay the patient on his back and lifted his legs. There is recommended a gastric lavage and / or reception of activated charcoal therapy aimed at correcting dehydration and violations of water-salt metabolism, supplementation of BCC.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: